

XCYTE THERAPIES INC  
Form 8-K  
October 08, 2004

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**  
**the Securities Act of 1934**

Date of Report (Date of earliest event reported): **October 7, 2004**

**XCYTE THERAPIES, INC.**  
*(Exact name of registrant as specified in its charter)*

**Delaware**  
*(State or other jurisdiction of*  
*incorporation or organization)*

**0-50626**  
**Commission**  
  
**File Number**

**91-1707622**  
*(I.R.S. Employer*  
*Identification Number)*

**1124 Columbia Street, Suite 130**

Edgar Filing: XCYTE THERAPIES INC - Form 8-K

**Seattle, Washington 98104**  
*(Address of principal executive offices and zip code)*

*(Registrant's telephone number, including area code)*      **(206) 262-6200**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01 Entry into a Material Definitive Agreement.**

On October 7, 2004, the Company entered into Amendment No. 5 to its Services Agreement with Lonza Biologics PLC ( Lonza ) dated June 6, 2000. Under the terms of the amendment, Lonza will provide certain process analyses and other services related to the manufacturing of antibodies used in the Company s Xcellerate Technology.

On October 7, 2004, the Company entered into Amendment No. 7 to its Services Agreement with Lonza dated June 6, 2000. Under the terms of the amendment, Lonza will provide certain process analyses and other services related to the manufacturing of antibodies used in the Company s Xcellerate Technology.

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits.

See Index to Exhibits attached hereto.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

XCYTE THERAPIES, INC.

By: /s/ Joanna S. Black

---

Joanna S. Black

*Duly Authorized Officer of Registrant*

*General Counsel, Vice President and  
Secretary*

Date: October 7, 2004

INDEX TO EXHIBITS

<u>Exhibit Number</u>	<u>Description of Document</u>
10.1	Amendment No. 7 dated October 7, 2004 to the Services Agreement dated June 6, 2000 between Xcyte Therapies, Inc. and Lonza Biologics PLC.
10.2	Amendment No. 5 dated October 7, 2004 to the Services Agreement dated June 6, 2000 between Xcyte Therapies, Inc. and Lonza Biologics PLC.

Certain information in these exhibits has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.